Intrexon Corp (NYSE:XON) COO Krish Krishnan purchased 20,900 shares of Intrexon Corp stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $14.21 per share, for a total transaction of $296,989.00. Following the purchase, the chief operating officer now directly owns 20,900 shares in the company, valued at approximately $296,989. Intrexon Corp (NYSE:XON) weekly performance is 13.65%. On last trading day company shares ended up $17.49. Analysts mean target price for the company is $30.00. Intrexon Corp (NYSE:XON) distance from 50-day simple moving average (SMA50) is -24.40%.
Albany Molecular Research (NASDAQ:AMRI) CEO William Marth purchased 30,000 shares of Albany Molecular Research stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $15.40 per share, with a total value of $462,000.00. Following the acquisition, the chief executive officer now directly owns 313,699 shares of the company’s stock, valued at approximately $4,830,965. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares advanced 1.96% in last trading session and ended the day on $15.62. AMRI gross Margin is 27.80% and its return on assets is 3.10%.Albany Molecular Research, Inc. (NASDAQ:AMRI) quarterly performance is 31.48%.
Corcept Therapeutics (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average cost of $1.84 per share, for a total transaction of $184,000.00. Following the completion of the transaction, the director now directly owns 578,389 shares in the company, valued at approximately $1,064,236. Corcept Therapeutics Incorporated (NASDAQ:CORT) shares moved up 4.86% in last trading session and was closed at $1.94, while trading in range of $1.84 – $1.97. Corcept Therapeutics Incorporated (NASDAQ:CORT) year to date (YTD) performance is -39.56%.
Durata Therapeutics (NASDAQ:DRTX) Director Schutter Richard U. De purchased 15,000 shares of Durata Therapeutics stock on the open market in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $15.57 per share, for a total transaction of $233,550.00. Following the acquisition, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $233,550. Durata Therapeutics Inc. (NASDAQ:DRTX) ended the last trading day at $15.65. Company weekly volatility is calculated as 4.78% and price to cash ratio as 6.97.Durata Therapeutics Inc. (NASDAQ:DRTX) showed a positive weekly performance of 12.59%.
Verastem (NASDAQ:VSTM) CEO Robert Forrester purchased 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The shares were purchased at an average price of $7.62 per share, for a total transaction of $7,620.00. Following the completion of the transaction, the chief executive officer now directly owns 239,320 shares of the company’s stock, valued at approximately $1,823,618. Verastem Inc. (NASDAQ:VSTM) shares advanced 1.59% in last trading session and ended the day on $7.65. VSTM return on assets is -38.90%.Verastem Inc. (NASDAQ:VSTM) quarterly performance is -48.93%.